Skip to main content
Top
Published in: Journal of Neurology 12/2013

01-12-2013 | Original Communication

Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy

Authors: Maike F. Dohrn, Christoph Röcken, Jan L. De Bleecker, Jean-Jacques Martin, Matthias Vorgerd, Peter Y. Van den Bergh, Andreas Ferbert, Katrin Hinderhofer, J. Michael Schröder, Joachim Weis, Jörg B. Schulz, Kristl G. Claeys

Published in: Journal of Neurology | Issue 12/2013

Login to get access

Abstract

Familial amyloid polyneuropathy (FAP) is a progressive systemic autosomal dominant disease caused by pathogenic mutations in the transthyretin (TTR) gene. We studied clinical, electrophysiological, histopathological, and genetic characteristics in 15 (13 late-onset and two early-onset) patients belonging to 14 families with polyneuropathy and mutations in TTR. In comparison, we analysed the features of nine unrelated patients with an idiopathic polyneuropathy, in whom TTR mutations have been excluded. Disease occurrence was familial in 36 % of the patients with TTR-associated polyneuropathy and the late-onset type was observed in 86 % (mean age at onset 65.5 years). Clinically, all late-onset TTR-mutant patients presented with distal weakness, pansensory loss, absence of deep tendon reflexes, and sensorimotor hand involvement. Afferent-ataxic gait was present in 92 % leading to wheelchair dependence in 60 % after a mean duration of 4.6 years. Autonomic involvement was observed in 60 %, and ankle edema in 92 %. The sensorimotor polyneuropathy was from an axonal type in 82 %, demyelinating or mixed type in 9 % each. Compared to the TTR-unmutated idiopathic polyneuropathy patients, we identified rapid progression, early ambulatory loss, and autonomic disturbances, associated with a severe polyneuropathy as red flags for TTR–FAP. In 18 % of the late-onset TTR-FAP patients, no amyloid was found in nerve biopsies. Further diagnostic pitfalls were unspecific electrophysiology, and coincident diabetes mellitus (23 %) or monoclonal gammopathy (7 %). We conclude that a rapid disease course, severely ataxic gait, hand involvement, and autonomic dysfunction are diagnostic hallmarks of late-onset TTR–FAP. Genetic analysis should be performed even when amyloid deposits are lacking or when polyneuropathy-causing comorbidities are concomitant.
Appendix
Available only for authorised users
Literature
2.
go back to reference Schönland SO, Hegenbart U, Bochtler T et al (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119:488–493CrossRefPubMed Schönland SO, Hegenbart U, Bochtler T et al (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119:488–493CrossRefPubMed
3.
go back to reference Sommer C, Schröder JM (1989) Amyloid neuropathy: immunocytochemical localization of intra- and extracellular immunoglobulin light chains. Acta Neuropathol 79:190–199CrossRefPubMed Sommer C, Schröder JM (1989) Amyloid neuropathy: immunocytochemical localization of intra- and extracellular immunoglobulin light chains. Acta Neuropathol 79:190–199CrossRefPubMed
4.
go back to reference Linke RP (2012) On typing amyloidosis using immunohistochemistry. Detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem 47:61–132CrossRefPubMed Linke RP (2012) On typing amyloidosis using immunohistochemistry. Detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem 47:61–132CrossRefPubMed
5.
go back to reference Liz MA, Mar FM, Franquinho F, Sousa MM (2010) Aboard transthyretin: from transport to cleavage. IUBMB Life 62:429–435PubMed Liz MA, Mar FM, Franquinho F, Sousa MM (2010) Aboard transthyretin: from transport to cleavage. IUBMB Life 62:429–435PubMed
6.
go back to reference Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:4499–4503CrossRefPubMed Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:4499–4503CrossRefPubMed
7.
go back to reference Cardoso I, Goldsbury CS, Müller SA et al (2002) Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 317:683–695CrossRefPubMed Cardoso I, Goldsbury CS, Müller SA et al (2002) Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 317:683–695CrossRefPubMed
8.
go back to reference Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RMM (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 276:27207–27213CrossRefPubMed Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RMM (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 276:27207–27213CrossRefPubMed
9.
10.
go back to reference Conceiçao I, De Carvalho M (2007) Clinical variability in type I familial amyloid polyneuropathy (Val30 Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35:116–118CrossRefPubMed Conceiçao I, De Carvalho M (2007) Clinical variability in type I familial amyloid polyneuropathy (Val30 Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35:116–118CrossRefPubMed
11.
go back to reference Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 56:431–435CrossRefPubMed Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 56:431–435CrossRefPubMed
12.
go back to reference Westermark P, Sletten K, Johansson B, Cornwell GG (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87:2843–2845CrossRefPubMed Westermark P, Sletten K, Johansson B, Cornwell GG (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87:2843–2845CrossRefPubMed
13.
go back to reference Bulawa CE, Connelly S, DeVit M et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109:9629–9634CrossRefPubMed Bulawa CE, Connelly S, DeVit M et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109:9629–9634CrossRefPubMed
14.
go back to reference Coelho T, Maia L, da Martins Silva A (2010) Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid polyneuropathy. Amyloid 17:75–76CrossRef Coelho T, Maia L, da Martins Silva A (2010) Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid polyneuropathy. Amyloid 17:75–76CrossRef
16.
go back to reference Holmgren G, Steen L, Ekstedt J et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246CrossRefPubMed Holmgren G, Steen L, Ekstedt J et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246CrossRefPubMed
17.
go back to reference Holmgren G, Steen L, Suhr O et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113–1116CrossRefPubMed Holmgren G, Steen L, Suhr O et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113–1116CrossRefPubMed
18.
go back to reference Dubowitz V, Sewry C (2007) Histological and histochemical stains and reactions. Muscle biopsy a practical approach. Elsevier, Philadelphia, pp 3–39 Dubowitz V, Sewry C (2007) Histological and histochemical stains and reactions. Muscle biopsy a practical approach. Elsevier, Philadelphia, pp 3–39
19.
go back to reference Schröder JM, Hoheneck M, Weis J, Deist H (1985) Ethylene oxide polyneuropathy: clinical follow-up study with morphometric and electron microscopic findings in a sural nerve biopsy. J Neurol 232:83–90CrossRefPubMed Schröder JM, Hoheneck M, Weis J, Deist H (1985) Ethylene oxide polyneuropathy: clinical follow-up study with morphometric and electron microscopic findings in a sural nerve biopsy. J Neurol 232:83–90CrossRefPubMed
20.
go back to reference Weis J, Brandner S, Lammens M, Sommer C, Vallat J-M (2012) Processing of nerve biopsies: a practical guide for neuropathologists. Clin Neuropathol 31:7–23CrossRefPubMed Weis J, Brandner S, Lammens M, Sommer C, Vallat J-M (2012) Processing of nerve biopsies: a practical guide for neuropathologists. Clin Neuropathol 31:7–23CrossRefPubMed
21.
go back to reference Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–423CrossRefPubMed Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–423CrossRefPubMed
22.
go back to reference Jacobson DR, Pastore RD, Yaghoubian R et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466–473CrossRefPubMed Jacobson DR, Pastore RD, Yaghoubian R et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466–473CrossRefPubMed
23.
go back to reference Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM (2012) Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 45:26–31CrossRefPubMed Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM (2012) Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 45:26–31CrossRefPubMed
24.
go back to reference Cappellari M, Cavallaro T, Ferrarini M et al (2011) Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 16:119–129CrossRefPubMed Cappellari M, Cavallaro T, Ferrarini M et al (2011) Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 16:119–129CrossRefPubMed
25.
go back to reference Palaninathan SK, Mohamedmohaideen NN, Snee WC, Kelly JW, Sacchettini JC (2008) Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol 382:1157–1167CrossRefPubMed Palaninathan SK, Mohamedmohaideen NN, Snee WC, Kelly JW, Sacchettini JC (2008) Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol 382:1157–1167CrossRefPubMed
26.
go back to reference Wilkinson-White LE, Easterbrook-Smith SB (2007) Characterization of the binding of Cu(II) and Zn(II) to transthyretin: effects on amyloid formation. Biochemistry 46:9123–9132CrossRefPubMed Wilkinson-White LE, Easterbrook-Smith SB (2007) Characterization of the binding of Cu(II) and Zn(II) to transthyretin: effects on amyloid formation. Biochemistry 46:9123–9132CrossRefPubMed
27.
go back to reference Zhang Q, Kelly JW (2005) Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice? Biochemistry 44:9079–9085CrossRefPubMed Zhang Q, Kelly JW (2005) Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice? Biochemistry 44:9079–9085CrossRefPubMed
28.
go back to reference Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ (2000) Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119 M. Biochem Biophys Res Commun 270:1024–1028CrossRefPubMed Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ (2000) Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119 M. Biochem Biophys Res Commun 270:1024–1028CrossRefPubMed
29.
go back to reference Hammarström P, Jiang X, Hurshman Babbes AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99:16427–16432CrossRefPubMed Hammarström P, Jiang X, Hurshman Babbes AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99:16427–16432CrossRefPubMed
30.
go back to reference Hurshman Babbes AR, Powers ET, Kelly JW (2008) Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47:6969–6984CrossRefPubMed Hurshman Babbes AR, Powers ET, Kelly JW (2008) Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47:6969–6984CrossRefPubMed
31.
go back to reference Soares ML, Coelho T, Sousa A et al (2005) Susceptibility and modifier genes in Portuguese transthyretin V30 M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet 14:543–553CrossRefPubMed Soares ML, Coelho T, Sousa A et al (2005) Susceptibility and modifier genes in Portuguese transthyretin V30 M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet 14:543–553CrossRefPubMed
32.
go back to reference Sousa MM, Du Y, Fernandes R, Guimarães A, Stern D, Saraiva MJ (2001) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 21:7576–7586PubMed Sousa MM, Du Y, Fernandes R, Guimarães A, Stern D, Saraiva MJ (2001) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 21:7576–7586PubMed
33.
go back to reference Sousa MM, Saraiva MJ (2003) Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 71:385–400CrossRefPubMed Sousa MM, Saraiva MJ (2003) Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 71:385–400CrossRefPubMed
34.
go back to reference Koike H (2002) Type I (transthyretin met30) familial amyloid polyneuropathy in japan: early- vs late-onset form. Arch Neurol 59:1771–1776CrossRefPubMed Koike H (2002) Type I (transthyretin met30) familial amyloid polyneuropathy in japan: early- vs late-onset form. Arch Neurol 59:1771–1776CrossRefPubMed
35.
36.
go back to reference Koike H, Misu K, Sugiura M et al (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129–138CrossRefPubMed Koike H, Misu K, Sugiura M et al (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129–138CrossRefPubMed
37.
go back to reference Koike H, Ando Y, Ueda M et al (2009) Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 287:178–184CrossRefPubMed Koike H, Ando Y, Ueda M et al (2009) Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 287:178–184CrossRefPubMed
38.
go back to reference Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimarães A, Saraiva MJ (2006) Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 97:151–161CrossRefPubMed Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimarães A, Saraiva MJ (2006) Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 97:151–161CrossRefPubMed
39.
go back to reference Monteiro FA, Cardoso I, Sousa MM, Saraiva MJ (2006) In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett 580:3451–3456CrossRefPubMed Monteiro FA, Cardoso I, Sousa MM, Saraiva MJ (2006) In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett 580:3451–3456CrossRefPubMed
40.
go back to reference Sousa MM, Yan SD, Stern D, Saraiva MJ (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 80:1101–1110CrossRefPubMed Sousa MM, Yan SD, Stern D, Saraiva MJ (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 80:1101–1110CrossRefPubMed
41.
go back to reference Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 161:1935–1948CrossRefPubMed Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 161:1935–1948CrossRefPubMed
42.
go back to reference Stern D, Du Yan S, Fang Yan S, Marie Schmidt A (2002) Receptor for advanced glycation end products: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54:1615–1625CrossRefPubMed Stern D, Du Yan S, Fang Yan S, Marie Schmidt A (2002) Receptor for advanced glycation end products: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54:1615–1625CrossRefPubMed
43.
go back to reference Kodaira M, Sekijima Y, Tojo K et al (2008) Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome. J Peripher Nerv Syst 13:148–150CrossRefPubMed Kodaira M, Sekijima Y, Tojo K et al (2008) Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome. J Peripher Nerv Syst 13:148–150CrossRefPubMed
44.
go back to reference Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J (2006) Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 107:3489–3491CrossRefPubMed Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J (2006) Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 107:3489–3491CrossRefPubMed
45.
go back to reference Suhr OB, Ericzon B-G (2012) Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 19:78–80CrossRefPubMed Suhr OB, Ericzon B-G (2012) Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 19:78–80CrossRefPubMed
46.
go back to reference Koike H, Kawagashira Y, Iijima M et al (2008) Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol 255:1526–1533CrossRefPubMed Koike H, Kawagashira Y, Iijima M et al (2008) Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol 255:1526–1533CrossRefPubMed
Metadata
Title
Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy
Authors
Maike F. Dohrn
Christoph Röcken
Jan L. De Bleecker
Jean-Jacques Martin
Matthias Vorgerd
Peter Y. Van den Bergh
Andreas Ferbert
Katrin Hinderhofer
J. Michael Schröder
Joachim Weis
Jörg B. Schulz
Kristl G. Claeys
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 12/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-013-7124-7

Other articles of this Issue 12/2013

Journal of Neurology 12/2013 Go to the issue